Ben is Xconomy's Deputy Biotechnology Editor. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
Bind Therapeutics was one of the many biotechs to go public amidst the sector’s recent bull run. But while a number of companies have charged forward since, Bind has stumbled, and... Read more »
A group of biotech veterans have debuted today a new company, Homology Medicines, with a bold claim that their underlying science is a better version of the gene editing methods, such... Read more »
In biotech this Monday, all eyes were on an FDA advisory panel in Hyattsville, MD, where a throng of patient advocates some 800 strong gathered in support of approval for an... Read more »
It’s been a rocky 2016 for biotech, but so far lower valuations haven’t translated into large acquisitions. At least until this morning, when two of the world’s biggest pharma companies took... Read more »
Imagine that, heaven forbid, a blood vessel bursts inside your brain, spilling blood and causing pressure to build inside delicate tissues. You’ve just suffered the deadliest kind of stroke, what’s known... Read more »
In a close 7-6 vote, a committee of medical experts said today that eteplirsen, a drug to treat Duchenne muscular dystrophy, has not met the bar set by the FDA for... Read more »
It’s too early to call it a breakthrough, but for the first time, a gene therapy has been shown to have a real impact on patients with hemophilia A, the most... Read more »
Cerebral adrenoleukodystrophy is a rare, crippling neurological disease that leaves its patients, typically boys, severely disabled and ultimately dead in a matter of years. Only painful, dangerous bone marrow transplants can... Read more »
Chiasma was on the doorstep of possible of approval of its first drug, a potential treatment for a rare hormonal disorder called acromegaly. Now the Waltham, MA-based company is going to... Read more »
Gene editing was in the news again this week, thanks to Intellia Therapeutics, which looks poised to become the second company developing drugs with CRISPR-Cas9 technology to go public. It wouldn’t... Read more »
Cydan Development, New Enterprise Associates’s orphan drug startup accelerator, has taken a look at around 600 assets since it was formed some three years ago. Sifting through all these potential drugs... Read more »
It’s been a common sight over the past few years for a biotech startup to bring a bunch of “crossover” investors—who invest in both public and private companies—into the mix before... Read more »
Harvard University chemical biologist and serial entrepreneur Greg Verdine has spent more than a decade trying to come up with different solutions for one critical problem in biotech: The majority of... Read more »
What’s hot in Boston biotech? This year, it’s the challenges that lie ahead.
“What’s Hot in Boston Biotech” can change with the wind. One week it might be a multi-billion dollar buyout, the next a high profile startup. Keeping up with the latest high-flying... Read more »
This past week started out with a big alliance between Gilead Sciences and Nimbus Therapeutics in one of biotech’s biggest contests—the race to treat nonalcoholic steatohepatitis, or NASH. Those who packed... Read more »
Last week, we held our yearly Big Apple biotech event, “New York’s Life Science Disruptors,” which provides an inside look at the people and companies that are shaping the emerging life... Read more »
When Nimbus Therapeutics started out as a company called Nimbus “Discovery,” it was structured in a way that would allow it to easily sell one of its assets to an acquirer.... Read more »
It’s an understatement to call Amicus Therapeutics’ quest to get its first drug approved a roller coaster ride. But it looks like the twists and turns might soon be over for... Read more »
Our East Coast drive started in New York this week, where we took a close look at the state of the city’s biotech ecosystem and the road ahead through the eyes... Read more »
© 2007-2016, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.